Clinical Study
Effect of Preoperative Intravitreal Bevacizumab on the Surgical Outcome of Neovascular Glaucoma at Different Stages
Table 1
Baseline demographics and ocular characteristics of participants (total of 70 eyes).
| | Total ( eyes) | IVB group ( eyes) | Control ( eyes) | value (IVB versus control) |
| | Gender (male/female, number of patients) | 56/14 | 38/7 | 18/7 | 0.212 | | Age (years) | 58 ± 13 | 59 ± 10 | 57 ± 18 | 0.556 | | Causes of NVG, number (%) | | | | | | PDR | 47 (67) | 33 (73) | 14 (56) | | | CRVO | 8 (11) | 5 (11) | 3 (12) | 0.110 | | OIS | 12 (17) | 7 (16) | 5 (20) | | | Baseline IOP (mmHg) | 40.5 ± 9.2 | 40.3 ± 9.7 | 41.0 ± 8.4 | 0.759 | | Baseline BCVA (LogMAR) | 2.01 ± 1.11 | 1.96 ± 1.07 | 2.12 ± 1.20 | 0.556 | | Presence of NVA, number (%) | 66 (94) | 42 (93) | 24 (96) | 1.000 | | PAS extent, number (%) | | | | | | Less than 50% | 46 (66) | 35 (78) | 11 (44) | 0.004 | | More than 50% | 24 (34) | 10 (22) | 14 (56) | | | Preoperative PRP, number (%) | 56 (80) | 38 (84) | 18 (72) | 0.212 | | Postoperative follow-up (months) [range] | 27 ± 15 [12–68] | 26 ± 16 [12–68] | 27 ± 14 [12–67] | 0.721 |
|
|
IVB = intravitreal bevacizumab; NVG = neovascular glaucoma; PDR = proliferative diabetic retinopathy; CRVO = central retinal vein occlusion; OIS = ocular ischemic syndrome; IOP = intraocular pressure; BCVA = best-corrected visual acuity; MAR = minimal angle of resolution; NVA = neovascularization of angle; PAS = peripheral anterior synechiae; PRP = panretinal photocoagulation. Continuous variables are represented as mean ± standard deviation.
|
